Know Cancer

or
forgot password

Assessment of Physician Compliance to Recommended Liver Function Test Monitoring for Tykerb Patients


N/A
19 Years
N/A
Not Enrolling
Female
Metastatic Breast Cancer, Cancer

Thank you

Trial Information

Assessment of Physician Compliance to Recommended Liver Function Test Monitoring for Tykerb Patients


Inclusion Criteria:



- Female aged >= 19 years

- A diagnosis of breast cancer with documented metastatic disease (as defined by stage
at diagnosis, evidence of disease progression, and/or line of therapy);

- Documented order/prescription for lapatanib from January 1, 2007 - December 31, 2009;

- Received care at a practice utilizing the full electronic medical record capabilities
of US Oncology's iKnowMed system

Exclusion Criteria:

- Patients participating in clinical trials

- Patients receiving care for another cancer during the study time period

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

The change in proportion of patients that receive liver function tests prior to the initiation of lapatanib

Outcome Time Frame:

Within 30 days, 60 days, or 90 days prior to (and including) the day that lapatanib was initiated

Safety Issue:

Yes

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United Kingdom: No Health Authority

Study ID:

115270

NCT ID:

NCT01462552

Start Date:

December 2010

Completion Date:

August 2011

Related Keywords:

  • Metastatic Breast Cancer
  • Cancer
  • lapatanib
  • liver function testing
  • Breast cancer
  • Breast Neoplasms

Name

Location